Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phenotypic evolution of circulating tumor plasma cells across MGUS, SMM and multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

SBSina BeerInstitute of Cancer ResearchBBBritta BesemerUniversity Children's Hospital TübingenCLClaudia LengerkeUniversity Children's Hospital Tübingen

Discussion

Loading...

Member takes

Overview

Research shows phenotypic profiling of circulating tumor plasma cells across multiple myeloma stages, indicating evolving characteristics that impact treatment outcomes.

Key Points

  • To understand the phenotypic evolution of circulating tumor plasma cells across different stages of multiple myeloma.
  • Examined peripheral blood mononuclear cells from patients with MGUS, SMM, NDMM, and treated MM using 36-parameter spectral flow cytometry.
  • Analyzed differences in marker expression on plasma cells in paired bone marrow samples from NDMM patients.
  • CTPC counts increased with disease progression, whereas frequencies of normal plasma cells remained unchanged.
  • Distinct shifts in markers such as CD38 and CD56 were observed across disease stages, indicating maturation and transformation of plasma cells.
  • Markers associated with immune response and tolerance showed varying expression patterns, with implications for treatment outcomes.

Cite This Study

Beer et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1e4https://doi.org/10.1182/blood-2025-3914
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma2026
  2. 2Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights2025
  3. 3Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma2025
  4. 4Circulating plasma cells (polyclonal and monoclonal) as markers of an aggressive multiple myeloma phenotype2026
  5. 5Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden2025